{"abstract":"The Food and Drug Administration (FDA) is announcing a public meeting and an opportunity for public comment on Patient-Focused Drug Development for lung cancer. Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of lung cancer on daily life as well as the available therapies for lung cancer.","action":"Notice of public meeting; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2013/06/05/2013-13243.html","cfr_references":[],"citation":"78 FR 33851","comment_url":null,"comments_close_on":"2013-07-29","correction_of":null,"corrections":[],"dates":"The public meeting will be held on June 28, 2013, from 8:30 a.m. to 12:30 p.m. Registration to attend the meeting must be received by June 19, 2013 (see SUPPLEMENTARY INFORMATION for instructions). Submit electronic or written comments by July 29, 2013.","disposition_notes":null,"docket_ids":["Docket No. FDA-2013-N-0596"],"dockets":[],"document_number":"2013-13243","effective_on":null,"end_page":33852,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2013/06/05/2013-13243.xml","html_url":"https://www.federalregister.gov/documents/2013/06/05/2013-13243/lung-cancer-patient-focused-drug-development-public-meeting","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2013-13243?publication_date=2013-06-05","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2013-06-05/2013-13243/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":321,"last_updated":"2026-07-27 04:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2013-06-05/pdf/2013-13243.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2013-13243.pdf?1370350450","publication_date":"2013-06-05","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2013/06/05/2013-13243.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2013-N-0596","supporting_documents_count":0,"docket_id":"FDA-2013-N-0596","regulation_id_number":null,"title":"Lung Cancer Patient-Focused Drug Development: Public Meeting","checked_regulationsdotgov_at":"2013-06-25T08:06:44Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":33851,"subtype":null,"title":"Lung Cancer Patient-Focused Drug Development; Public Meeting","toc_doc":"Lung Cancer Patient-Focused Drug Development","toc_subject":"Meetings:","topics":[],"type":"Notice","volume":78}